tbuckley/cabot-search huggingface dataset:
DeepLensNet: Deep Learning Automated Diagnosis and Quantitative Classification of Cataract Type and Severity
Authors: Tiarnan D.L. Keenan, Qingyu Chen, Elvira Agrón, Yih-Chung Tham, Jocelyn Hui Lin Goh, Xiaofeng Lei, Yi Pin Ng, Yong Liu, Xinxing Xu, Ching-Yu Cheng, Mukharram M. Bikbov, Jost B. Jonas, Sanjeeb Bhandari, Geoffrey K. Broadhead, Marcus H. Colyer, Jonathan Corsini, Chantal Cousineau-Krieger, William Gensheimer, David Grasic, Tania Lamba, M. Teresa Magone, Michele Maiberger, Arnold Oshinsky, Boonkit Purt, Soo Y. Shin, Alisa T. Thavikulwat, Zhiyong Lu, Emily Y. Chew, Priscilla Ajilore, Alex Akman, Nadim S. Azar, William S. Azar, Bryan Chan, Victor Cox, Amisha D. Dave, Rachna Dhanjal, Mary Donovan, Maureen Farrell, Francisca Finkel, Timothy Goblirsch, Wesley Ha, Christine Hill, Aman Kumar, Kristen Kent, Arielle Lee, Pujan Patel, David Peprah, Emma Piliponis, Evan Selzer, Benjamin Swaby, Stephen Tenney, Alexander Zeleny
Journal: Ophthalmology (2022)
Quantifying SLE renal biopsy results aids clinician
Authors: H. Page
Journal: JAMA (1982)

A chronicity index based on renal biopsy appears to be a "very strong" predictor of outcome for patients with nephritis secondary to systemic lupus erythematosus (SLE), according to Simon Carette, MD, a fellow at the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases (NIADDKD), Bethesda, Md. Speaking in Washington, DC, at the Pan-American Congress of Rheumatology for himself and NIADDKD co-workers, Carette described a long-term study showing that only patients with low to moderate chronicity levels did well when treated with cytotoxic drugs. Fifty-three patients were entered in the seven-year study. Requirements for admission included (1) a diagnosis of SLE by American Rheumatism Association criteria and (2) kidney disease unaccounted for by other pathological processes and confirmed by laboratory tests and biopsy specimens. The patients were randomized to receive one of three programs: azathioprine, up to 4 mg/kg/day, plus prednisone, up to 0.5 mg/kg/day; cyclophosphamide, up to 4
Classified Advertising
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Creutzfeldt-Jakob disease
Authors: Ruth Gilbert, Peter Fleming, Jem Berry, Peter Rudd
Journal: BMJ (1990)

study.Similar high figures have been found for the whole South Western region (2 64/1000 in 1987; data provided by the regional information unit).The reason for the high incidence of the syndrome in Avon is unclear but may in part be due to the fact that equivocal findings are less likely to be recorded as a cause of death.If government recommendations to establish a paediatric patholo- gist in each region are implemented the difference between the incidence in Avon and elsewhere may diminish.
Elevated levels of hemostatic markers in elderly patients with atrial fibrillation who received adjusted dose warfarin Keiko Nakagawa, Tadakazu Hirai, Yoshiko Uchiyama, Tomoki Kameyama, Noriko Shinokawa, Syutaro Takashima, Takashi Nozawa, Hidetsugu Asanoi, Hiroshi Inoue. Toyama Medical and Pharmaceutical University, Toyama, Japan
Journal: Journal of the American College of Cardiology (2001)
Massachusetts Medical Society
Authors: Herrman Blumgart
Journal: New England Journal of Medicine (1977)

Herrman Blumgart began his career under the tutelage of Henry Christian at the Peter Bent Brigham Hospital and of Francis Peabody at the Thorndike Laboratory, where he made his first contribution to cardiology. Both institutions harbored vigorous minds in profusion. It was the era of Harvey Cushing's mushrooming productivity in neurophysiology and neurosurgery, of Walter Cannon's momentous contributions to the physiology of the sympathetic nervous system, of Minot and Castle's hematologic discoveries, and of the first elective surgical treatment of a cardiac defect by Elliott Cutler.The Beth Israel Hospital was then a small, unpretentious community hospital in Roxbury, but . . .
Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.
Authors: Chunyi Hao, Chengyou Du, Baogang Peng, Wu Zhang, Yunfeng Shan, Ang Lv, Jianhui Wu, Changzhen Shang, Xuan Luo, Jinxing Wei, Heng Xiao, Jianguo Qiu, Yunpeng Hua, Shunli Shen, Ting Wang, Shengjie Dai, Xiang Chen, Shican Yan, Chunyi Hao
Journal: Journal of Clinical Oncology (2022)

435 Background: Anti-PD-1/PD-L1 combining with antiangiogenic agents has showed encouraging anti-tumor efficacy for treating advanced hepatocellular carcinoma (HCC). Toripalimab, a humanized monoclonal antibody against PD-1, has already been approved for melanoma, nasopharyngeal carcinoma and urothelial carcinoma in China. Therefore, we aimed to assess the safety and efficacy of toripalimab plus bevacizumab as a first-line treatment for unresectable HCC. Methods: This is a multicenter, single-arm, open-label, phase II study. Patients with unresectable locally advanced or metastatic HCC, BCLC stage C or B, Child-Pugh stage A, ECOG PS ≤ 1, at least one measurable lesion, no prior systemic therapy, were enrolled and treated with toripalimab (240mg, IV, D1) plus bevacizumab (15 mg/kg, IV, D1) every 3 weeks as first-line treatment until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoints were tolerability and objective response rate (ORR, per RECIST 1.1 by investigators). The secondary endpoints included the ORR (per mRECIST by independent review committee), the disease control rate (DCR) and progressive free survival (PFS), DoR, time-to-progression (TTP), time-to-response (TTR) and OS. Tumor response was assessed every 6 weeks. Results: As the data cut-off dateofJune 23, 2021,54 pts were enrolled (males 48; median age 54 years [range 26-68]; ECOG PS 0-1; 87.0% with HBV infection; 74.1% in BCLC stage C; 74.1% had received previous local treatment). All pts received at least one cycle of toripalimab plus bevacizumab treatment with median cycles 10 [range 1-18]. Among 52 evaluable patients, per RECIST v1.1, ORR was 32.7% (17/52) with 1 CR and 16 PR, and DCR was 78.8% (41/52); per mRECIST, ORR was 46.2% (95% CI: 32.2-60.5%) and DCR was 94.2% (95% CI: 84.1-98.8%). The median PFS was 9.9 months (95%CI: 5.5-11.0) and median OS has not reached. Most treatment related adverse events (TRAEs) were grade 1-2. Grade ≥3 TRAEs occurred in 25.9% pts, SAEs occurred in 27.8% pts, and grade ≥3 irAEs occurred in 11.1% pts. No treatment-emergent adverse event (TEAE) leading to death occurred in the study. Conclusions: Toripalimab in combination with bevacizumab as first-line treatment showed promising antitumor activity in patients with advanced HCC, and a manageable safety profile. A randomized phase 3 trial of toripalimab plus bevacizumab versus sorafenib (NCT04723004) are ongoing to further validate the efficacy of combination as first-line treatment in advanced HCC patients. Clinical trial information: NCT04605796.
Appointments
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COVID-19 in India: the dangers of false optimism
Authors: None The Lancet
Journal: The Lancet (2020)

Despite a strong response at the outset of the pandemic, as of Sept 22, India has the world's fastest growing outbreak of COVID-19 in absolute numbers according to WHO, reporting more than 5·6 million infections. Restrictions began to be lifted in June, and this relaxation has continued in the face of a continuing dramatic increase in case numbers nationally. Beneath these alarming national figures, the pattern of spread in India is nuanced and complex, with marked differences between states, and between rural and urban areas.
Immunity to Invasive Fungal Diseases
Authors: Arturo Casadevall
Journal: Annual Review of Immunology (2022)

Invasive fungal diseases are rare in individuals with intact immunity. This, together with the fact that there are only a few species that account for most mycotic diseases, implies a remarkable natural resistance to pathogenic fungi. Mammalian immunity to fungi rests on two pillars, powerful immune mechanisms and elevated temperatures that create a thermal restriction zone for most fungal species. Conditions associated with increased susceptibility generally reflect major disturbances of immune function involving both the cellular and humoral innate and adaptive arms, which implies considerable redundancy in host defense mechanisms against fungi. In general, tissue fungal invasion is controlled through either neutrophil or granulomatous inflammation, depending on the fungal species. Neutrophils are critical against Candida spp. and Aspergillus spp. while macrophages are essential for controlling mycoses due to Cryptococcus spp., Histoplasma spp., and other fungi. The increasing number of immunocompromised patients together with climate change could significantly increase the prevalence of fungal diseases.
Percutaneous coronary intervention versus coronary bypass graft surgery: Outcome of diabetics in the AWESOME randomized trial and registry Steven P. Sedlis, Douglass A Morrison, Gulshan Sethi, Jerome Sacks, William Henderson, Frederick Grover, Rick A. Esposito, for the investigators and Patients of VA cooperative #385 (AWESOME). New York VA Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Free Papers
Authors: G. Bouachour, P. Tirot, M. Guiraud, D. Simonin, C. Haas, P. Alquier, B. Santak, J. Vogt, U. Wachter, D. Vassilev, M. Georgieff, P. Radermacher, D. Annane, E. Béllissant, B. Mathieu, J. C. Raphael, Ph. Gajdos, O. Eichelbrönner, H. Reinelt, H. Wiedeck, R. Rossaint, A. Leighton, D. Pittet, P. M. Suter, J. Garbino, K. Reinhart, E. Abraham, L. Fischer, M. P. Glauser, T. Dugemier, B. Tayag, S. Athanasiou, S. Staeger
Journal: Intensive Care Medicine (1996)
Upconversion nanoparticles@AgBiS2 core-shell nanoparticles with cancer-cell-specific cytotoxicity for combined photothermal and photodynamic therapy of cancers
Authors: Zhaoyou Chu, Tian Tian, Zhenchao Tao, Juan Yang, Benjin Chen, Hao Chen, Wanni Wang, Peiqun Yin, Xiaoping Xia, Hua Wang, Haisheng Qian
Journal: Bioactive Materials (2022)

UCNPs@AgBiS
AMA Specialty Journal Abstracts
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Dysfunctional Health Benefits Market and Implications for US Employers and Employees
Authors: David Scheinker, Arnold Milstein, Kevin Schulman
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physical activity and coronary calcium: The cedars-sinai cardiovascular observational study Arlene Ledesma, Enrique F. Schisterman, Howard C. Lewin, Sean W. Hayes, John D. Friedman, Guido Germano, Ishac Cohen, Romalisa S. Miranda, Amy M. Gallagher, Daniel S. Berman. Cedars-Sinai Medical Center, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation
Authors: Brian M. Dulmovits, Yuefeng Tang, Julien Papoin, Mingzhu He, Jianhua Li, Huan Yang, Meghan E. Addorisio, Lauren Kennedy, Mushran Khan, Elena Brindley, Ryan J. Ashley, Cheryl Ackert-Bicknell, John Hale, Ryo Kurita, Yukio Nakamura, Betty Diamond, Betsy J. Barnes, Olivier Hermine, Patrick G. Gallagher, Laurie A. Steiner, Jeffrey M. Lipton, Naomi Taylor, Narla Mohandas, Ulf Andersson, Yousef Al-Abed, Kevin J. Tracey, Lionel Blanc
Journal: Blood (2022)
Anniversary ARM.
Journal: BMJ (1982)

Would Sir Charles Hastings have been proud of his vigorous offspring that celebrated its 150th annual meeting from 5 to 8 July in London?He would certainly have overheard his name spoken with respect during the medicopolitical, scientific, and social exchanges that made up the 1982 Annual Representative Meeting (p 308).He would undoubtedly have been pleasantly surprised at the wide range of subjects-especially those on science and public health-debated by representatives, have welcomed the well-ordered and democratic way in which the debates were conducted, and admired the determination of so many doctors from so many places in Britain and overseas to get to the meeting despite the train strike.The BMA's founder would also have been proud that his association had a prince at its head for the second time, and he would surely have applauded HRH the Prince of Wales's succinct and sensitive presidential address, in which he reminded the audience of 2000 at the Royal Festival Hall on 7 July about the health needs of minority groups and of the disabled ( 17July, p 185).The Representative Body is the BMA's supreme policy- making body-the doctors' parliament as it is often described.But its members, elected from all crafts and all parts of the country, face a Herculean task in trying to distil policies from the 600 or so items on the annual agenda, with subjects that this year ranged from the crucial one of medical manpower to a demand to increase the death grant "from £30 to a more realistic level."Many motions are never debated; the ARM's efforts to debate its agenda in a constructive way have, however, become much more effective in recent years, and its work has been helped by the development of annual conferences for all the crafts, where many "nuts and bolts" motions relating specifically to a particular craft are dealt with.This year the Representative Body's new chairman, Dr J H Marks, and his deputy, Mr James Kyle, kept a tight but humorous rein on the proceedings and led the 450 or so repre- sentatives through the most important sections of the agenda.Even so, the delicate balance between the freedom to debate a subject adequately and the need to deal with a long list of essential policy items was not easy to maintain.Furthermore, the strengthening of the profession's craft structure has increased the scope for sectional interests within the profession to develop their own distinctive policies, and this has made the Representative Body's function as a policy-deciding forum for the whole profession both more important and more difficult, adding to the chairman's burden.Events during the session and decisions at craft conferences
Prenatal Exposure to Antipsychotics—Handle With Caution—Reply
Authors: Zixuan Wang, Ian C. K. Wong, Kenneth K. C. Man
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Skeleton-secreted PDGF-BB mediates arterial stiffening
Authors: Lakshmi Santhanam, Guanqiao Liu, Sandeep Jandu, Weiping Su, Bulouere P. Wodu, William Savage, Alan Poe, Xiaonan Liu, Lacy M. Alexander, Xu Cao, Mei Wan
Journal: Journal of Clinical Investigation (2021)

Evidence links osteoporosis and cardiovascular disease but the cellular and molecular mechanisms are unclear. Here we identify skeleton-secreted platelet-derived growth factor–BB (PDGF-BB) as a key mediator of arterial stiffening in response to aging and metabolic stress. Aged mice and those fed high-fat diet (HFD), relative to young mice and those fed normal chow food diet, respectively, had higher serum PDGF-BB and developed bone loss and arterial stiffening. Bone/bone marrow preosteoclasts in aged mice and HFD mice secrete an excessive amount of PDGF-BB, contributing to the elevated PDGF-BB in blood circulation. Conditioned medium prepared from preosteoclasts stimulated proliferation and migration of the vascular smooth muscle cells. Conditional transgenic mice, in which PDGF-BB is overexpressed in preosteoclasts, had 3-fold higher serum PDGF-BB concentration and developed simultaneous bone loss and arterial stiffening spontaneously at a young age. Conversely, in conditional knockout mice, in which PDGF-BB is deleted selectively in preosteoclasts, HFD did not affect serum PDGF-BB concentration; as a result, HFD-induced bone loss and arterial stiffening were attenuated. These studies confirm that preosteoclasts are a main source of excessive PDGF-BB in blood circulation during aging and metabolic stress and establish the role of skeleton-derived PDGF-BB as an important mediator of vascular stiffening.
Novel Insights on Obligate Symbiont Lifestyle and Adaptation to Chemosynthetic Environment as Revealed by the Giant Tubeworm Genome
Authors: André Luiz de Oliveira, Jessica Mitchell, Peter Girguis, Monika Bright
Journal: Molecular Biology and Evolution (2021)

Abstract The mutualism between the giant tubeworm Riftia pachyptila and its endosymbiont Candidatus Endoriftia persephone has been extensively researched over the past 40 years. However, the lack of the host whole-genome information has impeded the full comprehension of the genotype/phenotype interface in Riftia. Here, we described the high-quality draft genome of Riftia, its complete mitogenome, and tissue-specific transcriptomic data. The Riftia genome presents signs of reductive evolution, with gene family contractions exceeding expansions. Expanded gene families are related to sulfur metabolism, detoxification, antioxidative stress, oxygen transport, immune system, and lysosomal digestion, reflecting evolutionary adaptations to the vent environment and endosymbiosis. Despite the derived body plan, the developmental gene repertoire in the gutless tubeworm is extremely conserved with the presence of a near intact and complete Hox cluster. Gene expression analyses establish that the trophosome is a multifunctional organ marked by intracellular digestion of endosymbionts, storage of excretory products, and hematopoietic functions. Overall, the plume and gonad tissues both in contact to the environment harbor highly expressed genes involved with cell cycle, programed cell death, and immunity indicating a high cell turnover and defense mechanisms against pathogens. We posit that the innate immune system plays a more prominent role into the establishment of the symbiosis during the infection in the larval stage, rather than maintaining the symbiostasis in the trophosome. This genome bridges four decades of physiological research in Riftia, whereas it simultaneously provides new insights into the development, whole organism functions, and evolution in the giant tubeworm.
Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
Authors: Vandana Sachdev, Amita Kulshreshtha, Julia W Cohen, Doug R Rosing, Stanislav Sidenko, Cindy Delbrook, Brandon Wiley
Journal: Journal for ImmunoTherapy of Cancer (2020)

Correction: Outcomes and biomarker analyses among patients with